Highlights
About
Intranasal Drug-delivery Platform
SipNose focuses on nose-to-brain medical applications and is developing a nasal delivery platform for local, systemic, and central nervous system indications. The company’s intranasal drug-delivery platform uses a mechanism designed to improve efficacy, patient compliance, and safety.
SipNose’s noninvasive devices are designed to ensure accurate dose delivery via the nasal cavity and incorporate a simple, efficient mechanism to allow localization of the aerosolized drug in the olfactory epithelium, resulting in better absorption into the olfactory bulb and brain.
The company’s technology enables drug molecules of vast chemical and pharmaceutical characteristics to reach the brain faster and more efficiently with higher safety and improved patient experience.
Identity
| Name | SipNose |
|---|---|
| Slug | sipnose |
| Type / kind | startup |
| Crunchbase ID | sipnose |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP6q-40KDA |
Status
| Status | acquired |
|---|---|
| Status reason | Acquired by Aptar Pharma on Oct, 2024 |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | North District |
| HQ city | Yokne'am Illit |
| HQ address | 13 Hayetzira St., Yokne'am Illit, Israel |
Web & social
| Website | https://sipnose.com |
|---|---|
| https://www.linkedin.com/company/66605840 |
Classifications
Funding
| Total raised | — |
|---|---|
| Current stage | Acquired |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}